Adinazolam (BioDeep_00000018205)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine

化学式: C19H18ClN5 (351.1250658)
中文名称: 阿地唑仑
谱图信息: 最多检出来源 Homo sapiens(blood) 50%

分子结构信息

SMILES: CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
InChI: InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3

描述信息

Adinazolam is only found in individuals that have used or taken this drug. It is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives
C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine
C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

同义名列表

4 个代谢物同义名

({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine; Adinazolamum; ADINAZOLAM



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Marco Antonioli, Joanna Rybka, Livia A Carvalho. Neuroimmune endocrine effects of antidepressants. Neuropsychiatric disease and treatment. 2012; 8(?):65-83. doi: 10.2147/ndt.s16409. [PMID: 22347798]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Viera Lukacova, Walter S Woltosz, Michael B Bolger. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. The AAPS journal. 2009 Jun; 11(2):323-34. doi: 10.1208/s12248-009-9107-2. [PMID: 19430911]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Massimiliano Germani, Patrizia Crivori, Maurizio Rocchetti, Philip S Burton, Alan G E Wilson, Mark E Smith, Italo Poggesi. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2007 Jul; 31(3-4):190-201. doi: 10.1016/j.ejps.2007.03.008. [PMID: 17481865]
  • Karthik Venkatakrishnan, Kerry E Culm, Bruce L Ehrenberg, Jerold S Harmatz, Kathleen E Corbett, Joseph C Fleishaker, David J Greenblatt. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. Journal of clinical pharmacology. 2005 May; 45(5):529-37. doi: 10.1177/0091270004269105. [PMID: 15831776]
  • A D Fraser, W Bryan. Evaluation of the Abbott TDx serum benzodiazepine immunoassay for the analysis of lorazepam, adinazolam, and N-desmethyladinazolam. Journal of analytical toxicology. 1995 Sep; 19(5):281-4. doi: 10.1093/jat/19.5.281. [PMID: 7500613]
  • P L Golden, P E Warner, J C Fleishaker, R C Jewell, S Millikin, J Lyon, K L Brouwer. Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans. Clinical pharmacology and therapeutics. 1994 Aug; 56(2):133-41. doi: 10.1038/clpt.1994.116. [PMID: 8062489]
  • J H Chambers, J C Fleishaker. The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam. Biopharmaceutics & drug disposition. 1994 May; 15(4):263-72. doi: 10.1002/bdd.2510150402. [PMID: 8068865]
  • A D Fraser, A F Isner, W Bryan. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC. Journal of analytical toxicology. 1993 Nov; 17(7):427-31. doi: 10.1093/jat/17.7.427. [PMID: 8309217]
  • J C Fleishaker, T A Sisson, J J Sramek, J Conrad, A E Veroff, N R Cutler. Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery. Journal of clinical pharmacology. 1993 May; 33(5):463-9. doi: 10.1002/j.1552-4604.1993.tb04689.x. [PMID: 8331205]
  • S M Stahl, R L Hauger, J L Rausch, J C Fleishaker, E Hubbell-Alberts. Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clinical neuropharmacology. 1993; 16 Suppl 3(?):S19-31. doi: . [PMID: 8131152]
  • J C Fleishaker, L K Hulst, S A Ekernäs, A Grahnén. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. Journal of clinical psychopharmacology. 1992 Dec; 12(6):403-14. doi: NULL. [PMID: 1474178]
  • S H Kennedy, G M Brown. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiatry research. 1992 Aug; 43(2):177-85. doi: 10.1016/0165-1781(92)90132-m. [PMID: 1410073]
  • A B Suttle, S S Songer, G E Dukes, L J Hak, M Koruda, J C Fleishaker, K L Brouwer. Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. Journal of clinical psychopharmacology. 1992 Aug; 12(4):282-7. doi: NULL. [PMID: 1527233]
  • J C Fleishaker, C E Wright. Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administration. Pharmaceutical research. 1992 Apr; 9(4):457-63. doi: 10.1023/a:1015875910222. [PMID: 1495889]
  • M J Krieman, D M Hershock, I J Greenberg, W H Vogel. Effects of adinazolam on plasma catecholamine, heart rate and blood pressure responses in stressed and non-stressed rats. Neuropharmacology. 1992 Jan; 31(1):33-8. doi: 10.1016/0028-3908(92)90157-k. [PMID: 1542400]
  • J C Fleishaker, L K Hulst, T C Smith, H Friedman. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in health volunteers. European journal of clinical pharmacology. 1992; 42(3):287-94. doi: 10.1007/bf00266350. [PMID: 1577047]
  • P D Kroboth, R A Maxwell, J C Fleishaker, D H Van Thiel, R B Smith. Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects. Journal of clinical pharmacology. 1991 Jun; 31(6):580-6. doi: 10.1002/j.1552-4604.1991.tb03741.x. [PMID: 1880225]
  • J C Fleishaker, H Friedman, S R Pollock. Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers. Pharmaceutical research. 1991 Feb; 8(2):162-7. doi: 10.1023/a:1015875516834. [PMID: 2023863]
  • C L DeVane, M R Ware, R B Lydiard. Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacology bulletin. 1991; 27(4):463-73. doi: NULL. [PMID: 1687613]
  • S H Kennedy, J de Groot, E Ralevski, K Reed. A comparison of adinazolam and desipramine in the treatment of major depression. International clinical psychopharmacology. 1991; 6(2):65-76. doi: 10.1097/00004850-199100620-00001. [PMID: 1960382]
  • J C Fleishaker, H Friedman, S R Pollock, T C Smith. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteers. Clinical pharmacology and therapeutics. 1990 Dec; 48(6):652-64. doi: 10.1038/clpt.1990.209. [PMID: 2249377]
  • J C Fleishaker, J P Phillips, H S Lau. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping. Biopharmaceutics & drug disposition. 1990 Nov; 11(8):715-27. doi: 10.1002/bdd.2510110807. [PMID: 2271747]
  • M Linnoila, J M Stapleton, R Lister, H Moss, E Lane, A Granger, D J Greenblatt, M J Eckardt. Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. European journal of clinical pharmacology. 1990; 38(4):371-7. doi: 10.1007/bf00315578. [PMID: 2344860]
  • J C Fleishaker, J P Phillips, T C Smith, R B Smith. Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects. Pharmaceutical research. 1989 May; 6(5):379-86. doi: 10.1023/a:1015975214070. [PMID: 2748528]
  • J C Fleishaker, J P Phillips. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology. 1989; 99(1):34-9. doi: 10.1007/bf00634449. [PMID: 2506603]
  • M J Owens, G Bissette, C B Nemeroff. Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse (New York, N.Y.). 1989; 4(3):196-202. doi: 10.1002/syn.890040304. [PMID: 2575286]
  • J G Wagner. New and simple method to predict dosage of drugs obeying simple Michaelis-Menten elimination kinetics and to distinguish such kinetics from simple first order and from parallel Michaelis-Menten and first order kinetics. Therapeutic drug monitoring. 1985; 7(4):377-86. doi: 10.1097/00007691-198512000-00003. [PMID: 4082237]
  • G W Peng. Assay of adinazolam in plasma by liquid chromatography. Journal of pharmaceutical sciences. 1984 Aug; 73(8):1173-5. doi: 10.1002/jps.2600730840. [PMID: 6491930]
  • R A Lahti, V H Sethy, C Barsuhn, J B Hester. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology. 1983 Nov; 22(11):1277-82. doi: 10.1016/0028-3908(83)90200-9. [PMID: 6320036]